Though DVL proteins are significant drivers of oncogenic Wnt signaling, little is known about their mechanistic interactions with the HER2 signaling pathway and their ultimate role in modulating tumor immunity and disease progression in HER2-positive (HER2+) breast cancers. This evidence concerns the gene ERBB2 and breast cancer.